Lilly expects Q2 acquired IPR&D charge of about $2.8 billion pretax, $3.02/sh hit

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly expects Q2 2026 acquired IPR&D charges of about USD 2.8 billion on a pre-tax basis.
  • The charge is forecast to cut both GAAP and non-GAAP EPS by about USD 3.02.
  • The estimate reflects anticipated costs tied to collaborations, licensing deals, or other asset acquisitions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.